Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Defining the genetic network of candidate therapeutics CX-3543 and CX-5461

FY 2015-16

Summary
Genomic instability is an enabling characteristic of cancer and one new strategy in cancer therapy has focused on selectively killing the cancer cells by inhibiting nucleolus. CX-5461 and CX-3543 are two candidates anti-cancer drugs which are found to selectively kill cells lacking DNA repair genes. CX-5461 is a selective inhibitor of RNA PoII and CX-3543 is a direct inhibitor of rRNA biogenesis. Therefore, to develop these drugs as potential cancer treatments, it is crucial to understand their mechanism of action and identify genetic markers for the cellular sensitivity of CX- drugs. Our preliminary data indicates the deletion of DNA repair genes RAD51 or RAD52 in yeast makes cells hypersensitive to CX- drugs so the hypothesis is CX-5461 and CX-3543 selectively kill cancer cells by blocking replication of G4-DNA structures, causing DNA damage. I will use Saccharomyces cerevisiae as a model system because it can easily be genetically manipulated and has conserved genome maintenance pathways. Genomic instability assays are going to be done for understanding the mechanisms of CX-5461 and CX-3543 induced genome instability in yeast. The whole yeast genome will also be sequenced to understand the mutation pattern in the CX- drug-treated cells. To generate the complete map of yeast mutant strain sensitivity or resistance to the CX-drugs, a chemical genomic screen of all available yeast heterozygous and homozygous diploid deletion mutants is going to be performed. Finally, the hits from the chemical screen will be validated by quantitative growth curves analysis with and without CX-3543 or -5461. This research will create a genome-wide view of cellular pathways impacted by each drug and permit direct tests of the drug mechanism-of-action.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
350117
Name
Zhang Anni
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Defining the genetic network of candidate therapeutics CX-3543 and CX-5461
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Cancer Drugs; Cancer Therapy; Drug Sensitivity; Gene Mutations; Genomic Instability; Ribosome Biogenesis Inhibitor; Saccharomyces Cerevisiae
Abstract
Genomic instability is an enabling characteristic of cancer and one new strategy in cancer therapy has focused on selectively killing the cancer cells by inhibiting nucleolus. CX-5461 and CX-3543 are two candidates anti-cancer drugs which are found to selectively kill cells lacking DNA repair genes. CX-5461 is a selective inhibitor of RNA PoII and CX-3543 is a direct inhibitor of rRNA biogenesis. Therefore, to develop these drugs as potential cancer treatments, it is crucial to understand their mechanism of action and identify genetic markers for the cellular sensitivity of CX- drugs. Our preliminary data indicates the deletion of DNA repair genes RAD51 or RAD52 in yeast makes cells hypersensitive to CX- drugs so the hypothesis is CX-5461 and CX-3543 selectively kill cancer cells by blocking replication of G4-DNA structures, causing DNA damage. I will use Saccharomyces cerevisiae as a model system because it can easily be genetically manipulated and has conserved genome maintenance pathways. Genomic instability assays are going to be done for understanding the mechanisms of CX-5461 and CX-3543 induced genome instability in yeast. The whole yeast genome will also be sequenced to understand the mutation pattern in the CX- drug-treated cells. To generate the complete map of yeast mutant strain sensitivity or resistance to the CX-drugs, a chemical genomic screen of all available yeast heterozygous and homozygous diploid deletion mutants is going to be performed. Finally, the hits from the chemical screen will be validated by quantitative growth curves analysis with and without CX-3543 or -5461. This research will create a genome-wide view of cellular pathways impacted by each drug and permit direct tests of the drug mechanism-of-action.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zhang, Anni
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~